Clinical trials
Rectal Adenocarcinoma clinical trials
Below are recruiting rectal adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 55 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05752136RecruitingPhase 3
Pre-surgery radiation plus immunotherapy and chemo for rectal cancer
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT05772481Recruiting
PET-MRI scan test for rectal cancer after pre-surgery treatment
This study looks at whether a special scan called PET-MRI can better show how rectal cancer responds to treatment given before surgery. If it works well, it could help doctors plan the right next steps after chemoradiotherapy.
StrasbourgAges 18–75 - NCT06631443Recruiting
Asian Watch-and-Wait Study for Rectal Cancer
This study is for people with rectal cancer who have had treatment like radiation or chemo and their tumor has disappeared or nearly disappeared. Instead of surgery right away, doctors will closely monitor the cancer with regular check-ups to make sure it stays gone.
Mumbai, MaharashtraAges 18 years+ - NCT04808323RecruitingPhase 1
MRI-guided radiation to help preserve organs in rectal cancer
This Phase 1 study tests a radiation treatment approach guided by MRI scans to help keep nearby organs functioning while treating rectal cancer. It is designed to find a safe, effective way to target the tumor and adjust treatment during the course of therapy.
Milwaukee, WisconsinAges 18 years+ - NCT06762405RecruitingPhase 3
Testing dostarlimab with short radiation for MSI rectal cancer
This trial tests a new approach: giving the immunotherapy drug dostarlimab along with a short course of radiation before surgery, with the goal of avoiding surgery in many patients. It is for people with a specific type of rectal cancer (MSI-H or dMMR) that has not spread to other organs.
DijonAges 18 years+ - NCT06637462Recruiting
Studying standard treatment response before rectal cancer surgery
This study looks at how rectal cancer responds to the usual chemotherapy and radiation given before surgery. It aims to learn if certain molecular features of your tumor can predict how well it responds to treatment.
Middletown, New JerseyAges 18 years+ - NCT06793137RecruitingPhase 2
Antibiotics before surgery for advanced rectal cancer
This trial tests if taking antibiotics before standard treatment can improve outcomes for people with advanced rectal cancer that requires surgery.
São Paulo, São PauloAges 18 years+ - NCT07458529RecruitingPhase 2
Chemoradiation plus immunotherapy with or without probiotics for rectal cancer
This trial tests adding an immunotherapy drug (tislelizumab) and a probiotic to standard chemoradiation for locally advanced rectal cancer that has not spread. The goal is to see if the probiotic helps the treatment work better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07339904Recruiting
Bowel Function After Rectal Cancer Surgery
This study follows people with rectal cancer who have surgery to remove part of the rectum. It looks at how bowel function changes over time, and whether different treatments before surgery affect recovery.
Edegem, AntwerpAges 18 years+ - NCT07675967Recruiting
Blood Cell Changes During Cancer Treatment
This study is for people with solid tumors who are about to start chemotherapy or radiation. It looks at how these treatments affect blood cells and may help doctors understand changes in blood health over time.
Boston, MassachusettsAges 18 years+ - NCT06854679Recruiting
MRI-guided radiation for rectal cancer
This trial tests a new way of giving radiation therapy for rectal cancer, using MRI scans to aim the radiation more precisely. It's for people who need chemotherapy and radiation before surgery, and it aims to make treatment more effective while reducing side effects.
Sutton, SurreyAges 18 years+ - NCT07750951RecruitingPhase 2
Combination therapy before surgery for advanced rectal cancer
This trial tests a combination of two immunotherapy drugs and chemotherapy given before surgery for a type of rectal cancer that has a specific genetic marker (MSI-H/dMMR). The goal is to shrink the tumor and improve the chances of successful surgery.
Xi'an, ShaanxiAges 18 years+ - NCT03961776Recruiting
MRI to monitor treatment response in rectal cancer
This trial tests whether an MRI scan done during chemoradiation can help doctors track how rectal cancer treatment is working. It may improve how they measure response early so treatment planning can be better tailored.
Los Angeles, CaliforniaAges 18 years+ - NCT06850090RecruitingPhase 3
Comparing two chemo drugs before radiation for rectal cancer
This trial tests if a newer chemo pill (TAS-102) works better than the standard pill (capecitabine) when given before radiation and surgery for rectal cancer. It is for people with stage II or III rectal cancer that has certain high-risk features.
Jinan, ShandongAges 18–75 - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
Birmingham, AlabamaAges 18 years+ - NCT06931808Enrolling by invitationPhase 4
Fecal transplant with chemo, radiation, and immunotherapy for advanced colon cancer
This study tests a combination of fecal microbiota transplant, chemotherapy, radiation, and immunotherapy (sintilimab) for people with locally advanced rectal cancer. The goal is to see if this approach improves treatment outcomes.
Ningbo, ZhejiangAges 18–75 - NCT04165772RecruitingPhase 2
Dostarlimab for locally advanced mismatch-repair deficient solid tumors
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
Hartford, ConnecticutAges 18 years+ - NCT07549399RecruitingPhase 3
Radiation, Chemotherapy, and Immunotherapy for Rectal Cancer
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
Guangzhou, GuangdongAges 18–75 - NCT07107815Enrolling by invitation
Predicting rectal cancer treatment response using MRI
This study uses advanced MRI scanning and computer analysis to predict how well rectal cancer might respond to treatments given before surgery. It may help doctors choose the best approach for you.
Beijing, Beijing MunicipalityAges Any age - NCT07474103Recruiting
Chemo, radiation, and immunotherapy for high-risk rectal cancer
This trial tests a treatment plan that combines chemotherapy, radiation, and an immunotherapy drug before surgery for people with high-risk locally advanced rectal cancer. The goal is to see if this approach can improve outcomes.
WuhanAges 18–75 - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06926374Recruiting
Robotic surgery for gastrointestinal and urologic conditions
This trial tests a new robotic surgery system for common operations on the colon, rectum, prostate, kidney, bladder, stomach, esophagus, gallbladder, and hiatal hernia. It may offer a less invasive option for patients who need surgery for these conditions.
Hong KongAges 18–80 - NCT07108348Recruiting
ADAR1 levels in rectal cancer
This study looks at a protein called ADAR1 in rectal cancer tissue. It aims to see how ADAR1 levels might be related to the cancer and help doctors understand the disease better.
Konya, MeramAges 18–90 - NCT07221058RecruitingPhase 1
Adaptive radiation boost study for rectal cancer
This study tests whether giving an extra, targeted radiation dose (adaptive radiation boost) after standard treatment can improve outcomes for people with rectal cancer. You may be eligible if you have stage T2-3 N0-1 rectal cancer and can undergo MRI scans and certain chemotherapies.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for rectal adenocarcinoma?
- Yes. Clin2 currently lists 55 recruiting rectal adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a rectal adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a rectal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.